Why is SLS down?
Down 6.3% today, while its drugmaker peers are up 1.2%; no story names it yet.
Rose on Nov 17
Up 156% on Nov 17 while the S&P 500 fell 1%.
“SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically.”